Research Analysts Set Expectations for CervoMed Q3 Earnings

Key Points

• Roth Capital has revised its Q3 2025 earnings per share estimate for CervoMed down to ($0.76), compared to a previous estimate of ($0.50).
• CervoMed's recent quarterly earnings report revealed a miss in analysts' estimates, posting an EPS of ($0.70) against a consensus of ($0.57).
• The company has a mixed rating from analysts, with an average rating of "Moderate Buy" and a consensus price target of $21.43.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Investment analysts at Roth Capital reduced their Q3 2025 earnings per share (EPS) estimates for CervoMed in a research note issued on Monday, August 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.76) per share for the quarter, down from their prior forecast of ($0.50). Roth Capital currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed's Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($2.51) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.71) EPS.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.45 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%.

A number of other research analysts have also recently issued reports on CRVO. Canaccord Genuity Group boosted their target price on CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Chardan Capital reissued a "buy" rating and issued a $15.00 target price on shares of CervoMed in a research note on Monday, August 11th. Finally, D. Boral Capital boosted their target price on CervoMed from $15.00 to $31.00 and gave the company a "buy" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.71.

CervoMed Stock Performance

NASDAQ:CRVO traded down $0.34 on Thursday, reaching $9.49. The company's stock had a trading volume of 66,985 shares, compared to its average volume of 2,057,662. CervoMed has a 1-year low of $1.80 and a 1-year high of $20.63. The firm has a market cap of $87.78 million, a PE ratio of -3.66 and a beta of -0.79. The business's 50-day moving average price is $7.78 and its two-hundred day moving average price is $7.28.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRVO. Jane Street Group LLC bought a new position in shares of CervoMed during the second quarter worth approximately $414,000. Marshall Wace LLP bought a new position in shares of CervoMed during the second quarter worth approximately $76,000. Thompson Davis & CO. Inc. bought a new position in shares of CervoMed during the second quarter worth approximately $91,000. Rhumbline Advisers increased its holdings in shares of CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after purchasing an additional 1,526 shares during the period. Finally, AQR Capital Management LLC bought a new position in shares of CervoMed during the first quarter worth approximately $227,000. 25.15% of the stock is owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.